Glaxo Group Limited

Glaxo Wellcome Inc.

Smithkline Beecham Corporation

Affymax Technologies, N.v.

Glaxosmithkline LLC

Christian M Gates

Peter J Schatz

William J Dower

Ronald W Barrett

Steven E Cwirla

Christopher R Wagstrom

Larry C Mattheakis

Qun Yin

Nicholas C Wrighton

David J Duffin

Palaniappan Balasubramanian

Surekha Podduturi

Sherril S Haselden

Richard Wayne Hendren

Randolph B DePrince

Willem P Stemmer

Millard G Cull

Jeff F Miller

Guy Lalonde

Christopher John Paddon

Gregory L Heinkel

Randoph B DePrince

Described are peptides and peptide mimetics that bind to and activate the thrombopoietin receptor. Such peptides and peptide mimetics are useful in methods for treating hematological disorders and particularly, thrombocytopenia resulting from chemotherapy, radiation therapy, or bone marrow transfusions as well as in diagnostic methods employing labeled peptides and peptide mimetics.

Peptides and compounds that bind to a receptor

Labeled compounds that bind to a thrombopoietin receptor

Receptors are peptides and peptide mimetics that bind to and activate the thrombopoietin receptor. Such peptides and peptide mimetics are useful in methods for treating hematological disorders and particularly, thrombocytopenia resulting from chemotherapy, radiation therapy, or bone marrow transfusions as well as in diagnostic methods employing labeled peptides and peptide mimetics.

Peptides and compounds that bind to a thrombopoietin receptor

The invention provides methods for screening libraries of complexes for compounds having a desired property, especially, the capacity to agonize, bind to, or antagonize a cellular receptor. The complexes in such libraries comprise a compound under test, a tag recording at least one step in synthesis of the compound, and a tether susceptible to modification by a reporter molecule. Modification of the tether is used to signify that a complex contains a compound having a desired property. The tag can be decoded to reveal at least one step in the synthesis of such a compound.

Use of modified tethers in screening compound libraries

A random peptide library constructed by transforming host cells with a collection of recombinant vectors that encode a fusion protein comprised of a DNA binding protein and a random peptide and also encode a binding site for the DNA. binding protein can be used to screen for novel ligands. The screening method results in the formation of a complex comprising the fusion protein bound to a receptor through the random peptide ligand and to the recombinant DNA vector through the DNA binding protein.

Peptide library and screening method

A random peptide library constructed by transforming host cells with a collection of recombinant vectors that encode a fusion protein comprised of a DNA binding protein and a random peptide and also encode a binding site for the DNA binding protein can be used to screen for novel ligands. The screening method results in the formation of a complex comprising the fusion protein bound to a receptor through the random peptide ligand and to the recombinant DNA vector through the DNA binding protein.

Growing community of inventors

Santa Cruz, CA, United States of America

Christian M Gates